GSK India Crosses INR 1000 cr In Topline, Key Portfolios Deliver 8.1% Growth in Q3 2025

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) announced its financial results for the third quarter ended December 31, 2025. The company witnessed growth across its key portfolios, driving overall topline expansion while managing profitability through cost discipline. Revenue from Operations was INR 1023 Crores and Profit After Tax (PAT) was INR 277 Crores. EBIDTA margins grew by 520bps to 35.9%. The General Medicines portfolio delivered competitive performance, with top five promoted brands growing ahead of the market. The Vaccines business saw market share expansion, and the Oncology business is gaining traction. The RUBY-1 trial established a new paradigm in first-line treatment of endometrial cancer, simplifying decision-making for healthcare practitioners and benefiting a wide range of endometrial cancer patients.